AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02317471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin+S-1
Description: Treatment will be start at the 5th week after the surgery.~S-1: 40\~60mg bid，d1\~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles.
Study NCT01281514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study NCT01281514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT01281514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV
Study NCT01281514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03758053 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03141138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-PIV
Description: Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
Study NCT03141138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-LAV F17
Description: Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible.
Study NCT04693494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: Training program consisting in 4 sessions with information about milestones to achieve and advices for motor development. Triptychs and short videos containing the main points containing the main points.
Study NCT02283554 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: open flap debridement (OFD)
Study NCT02283554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open flap debridement (OFD)
Study NCT02170571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Study NCT01314586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: secoisolariciresinol diglucoside-containing extract of flaxseed
Description: 0, 150 or 300 mg/day as 2 pills taken at breakfast and dinner, dietary counseling to comply with NCEP Step I diet
Study NCT01314586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: secoisolariciresinol diglucoside-containing extract of flaxseed
Description: 0, 150 or 300 mg/day as 2 pills taken at breakfast and dinner, dietary counseling to comply with NCEP Step I diet
Study NCT00832299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: 6 cycles of neo-adjuvant mFOLFOX6
Study NCT00832299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total mesorectal excision (TME)
Description: TME will be done 4-6 weeks after 6 cycles of neo-adjuvant FOLFOX.
Study NCT03144154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis + Self-care
Description: Our groupal intervention is divided into 8 weekly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
Study NCT04744246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: load carriage
Description: 35 pound load carried on the back
Study NCT04744246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: load carriage
Description: 35 pound load carried on the back
Study NCT02659254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus Target Eluting Bioresorbable Vascular Scaffold
Description: Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold
Study NCT01658436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235 (Stage 1)
Description: The investigational study drug used in this trial was BEZ235, which was supplied as 50mg, 200mg, 300mg, and 400mg solid dispersion sachets. Supply as 200mg and 50mg were provided for dose reduction. Patients were instructed to take the contents of one sachet of BEZ235 twice a day in the morning within 30 minutes after a light meal (breakfast).
Study NCT04311021 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03771924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inorganic phosphate
Description: Sodium phosphate
Study NCT03771924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Sodium chlorid
Study NCT00610298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration using a Galileo vibrating platform
Description: whole body vibration at 20 hertz for 3 minutes 3 to 5 days per week for up to 12 weeks
Study NCT01094847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1252
Description: tablet(oral) administration following the schedule of each arm
Study NCT01094847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWJ1252
Description: tablet(oral) administration following the schedule of each arm
Study NCT00013533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: >3 x 106/kg CD34+ stem cells by IV infusion
Study NCT03761992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gingko Baloba
Description: Tablets
Study NCT03761992 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study NCT03239392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNZ132-1-40
Description: Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15
Study NCT00035243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epothilone b
Description: EPO906 administered intravenously at 2.5 mg/m2 as a 5 minute bolus infusion repeated every week for three weeks followed by one week off The final tables and data is not in yet, so I cannot give you info on safety issues.
Study NCT03790202 — intervention group
Intervention type: DEVICE
Intervention: VistaCare®
Description: Controlled atmosphere wound healing device
Study NCT02283554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin (PRF)
Study NCT02283554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT03280667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus denosumab
Description: Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D
Study NCT03272425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad/allopurinol 200/300 FDC tablets
Description: Test Drug
Study NCT00655902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans fat (soy bean oil)
Description: Industrially produced trans fatty acid from soy bean oil (15 g/d for 16 weeks). The fat (a total of 25 g/d) will be baked into buns.
Study NCT00655902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control fat (sunflower oil)
Description: Control fat from sunflower oil, with 60% oleic acid (in total 25 g/d for 16 weeks). The fat will be baked into buns.
Study NCT00107341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study NCT00107341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00107341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00789425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (starch). A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
Study NCT03272425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 200 mg
Description: Comparator 1
Study NCT02904278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teen Pocket PATH® Mobile Application
Description: Participants in the intervention group will receive the mobile application for improving adherence to their post-transplant medications. The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken.
Study NCT02904278 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group: Standard of Care
Description: Adolescents and parents/guardians assigned to the Standard Care Condition will receive standard clinical care per standard site procedures.
Study NCT03272425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg
Description: Comparator 2
Study NCT04418648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab consolidation (240 mg) via iv infusion once every 3 weeks. Administration of toripalimab will commence on Day 1 following randomisation to toripalimab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 6 months.
Study NCT05395975 — intervention group
Intervention type: DEVICE
Intervention: Oxygen Reserve Index
Description: It is a new non-invasive and continuous measurement parameter that aims to provide information about the oxygen status of patients in the moderately hyperoxic range (100 mmHg\< PaO2 ≤ 200 mmHg).
Study NCT00567814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metyrapone
Description: Twice daily
Study NCT00567814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxazepam
Description: Twice Daily
Study NCT01224795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Description: Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to \< 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
Study NCT01224795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Peramivir, administered intravenously.
Study NCT02456077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Vaccine Program
Description: Efforts will be made to collaborate with pediatric and family medicine offices to utilize a multimodal intervention to improve adolescents' HPV immunization rates. As part of the overall intervention, four intervention strategies will be used: 1) a tailored website, iVac -HPV , 2) Motivational Interview Training for providers, 3) HPV Fact Sheets and 4) The Decision Aid for HPV Vaccines
Study NCT02647294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maxicor
Description: Patients with NAFLD will be randomly allocated to receive or n-3 PUFA (3,6 g/day, oral treatment) or placebo (1:1).
Study NCT00567814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily
Study NCT03678493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: Oral Capsule
Study NCT03678493 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study NCT02647294 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with NAFLD will be randomly allocated to receive or placebo or n-3 PUFA for 12 months (1:1).
Study NCT03999320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sophrology sessions
Description: 8 sophrology sessions, approximately 60 minutes each, spread over 12 months
Study NCT03999320 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: usual care
Study NCT04436952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: H7 coil
Description: The H7 coil arm will receive a medial prefrontal cortex (mPFC) DTMS 5 days a week for 8 consecutive weeks = 40 Sessions 20 Hz at 100% MT, 2 s on 20 s off intertrain interval, 50 trains, 2000 stimuli per session.
Study NCT04436952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H7 coil
Description: The H7 coil arm will receive a medial prefrontal cortex (mPFC) DTMS 5 days a week for 8 consecutive weeks = 40 Sessions 20 Hz at 100% MT, 2 s on 20 s off intertrain interval, 50 trains, 2000 stimuli per session.
Study NCT04436952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cool D-B80
Description: The Cool D-B80 arm will receive dorsomedial prefrontal cortex (DMPFC) rTMS 5 days a week for 8 consecutive weeks = 40 sessions 10 Hz at 120% MT, 5 s on 10 s off intertrain interval, 60 trains, First 3000 pulses to the left DMPFC then 3000 pulses to the right DMPFC. TMS will be done at active state by provocation
Study NCT04436952 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Response Prevention (ERP)
Description: The ERP will be conducted for 2 hours on week 1 and week 8 and for 1 hour on Weeks 2 to 7 for a total of 10 hours
Study NCT03203096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Magnesium citrate / Magnesium oxide
Study NCT03203096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04477096 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HS-10234
Description: HS-10234
Study NCT04477096 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Emtricitabine
Description: Emtricitabine
Study NCT01838096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THA using 4th generation CoC
Study NCT04198688 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intensive Smoking Cessation Intervention
Description: The intervention comprises 5-6 meetings during six weeks, and can be held in group or as an individual intervention. It is based on counselling and a clearly structured manual-based patient education programme taught by specially trained staff, and contains individual counselling on nicotine replacement therapy or other medical support, according to the level of dependence measured by the Fagerström test score. The first two weeks cover teaching sessions on: ambivalence and motivation, pros and cons of continuous smoking versus cessation, and a quit date is set between the 2. and 3. week. The last 3 sessions cover: risk situations, withdrawal symptoms and medical support for withdrawal symptoms, relapse prevention and how to handle a completely smoke-free life.
Study NCT02952820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lemborexant
Study NCT02952820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04193488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MTP block
Description: In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasagital scan, the block needle (50 mm 22 Gauge) will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.
Study NCT04193488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.
Study NCT04193488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Block group
Description: No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
Study NCT04692415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degludec
Description: treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
Study NCT00986765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovenox® (enoxaparin)
Description: Injectable solution 4000 UI
Study NCT00986765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspegic ® (Aspirin)
Description: 100 mg/day
Study NCT02382536 — intervention group
Intervention type: DEVICE
Intervention: BD Scarlett Infusion set
Description: Each subject will receive subcutaneous infusion from two investigational BD Scarlet infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
Study NCT02382536 — intervention group
Intervention type: DEVICE
Intervention: Medtronic QuickSet Infusion Set
Description: Each subject will receive subcutaneous infusion from two Medtronic infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
Study NCT03486834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160
Description: V160 was administered as a 0.5 mL (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant \[MAPA\], 4°C stable formulation) IM injection.
Study NCT03486834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution administered as a 0.5 mL IM injection
Study NCT03486834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution administered as a 0.5 mL IM injection
Study NCT04476797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 +SBRT
Description: 15 minute IV Infusion prior to SBRT
Study NCT04476797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo +SBRT
Description: 15 minute IV infusion prior to SBRT
Study NCT04692415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine U300
Description: treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
Study NCT03253965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metronome Normal
Description: Steps are timed with the beat of the metronome set to the subject's cadence
Study NCT03253965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metronome Slow
Description: Steps are timed with the beat of the metronome set to 85% of the subject's cadence
Study NCT03253965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metronome Fast
Description: Steps are timed with the beat of the metronome set to 115% of the subject's cadence
Study NCT03253965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Normal
Description: Steps are timed with the beat of the music by a rhythm consistent with the subject's cadence
Study NCT03253965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Slow
Description: Steps are timed with the beat of the music by a rhythm consistent with 85% of the subject's cadence
Study NCT03253965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Fast
Description: Steps are timed with the beat of the music by a rhythm consistent with 115% of the subject's cadence
Study NCT03253965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Auditory cueing
Description: Steps are not timed with any auditory cue.
Study NCT03226236 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: boost radiotherapy (XRT)
Description: Three daily doses boost radiotherapy (XRT) at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of vaccine+IL-2
Study NCT03226236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous DC vaccine
Description: The first dose (7 to 14 x 10_6 total dendritic cells) will be performed with freshly prepared vaccine, 9 days after leukapheresis; on day +1 starting from cycle 2 (3 weeks after the first cycle, on completion of QA assessments on the cryopreserved products), 5 additional doses will be administered every 3 weeks until maximum six vaccines.
Study NCT03226236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose IL-2
Description: high dose IL-2: 18 MIU/m2/day in 500cc administered by continuous IV infusion for 72 hours starting day +2.
Study NCT02873416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Study NCT02873416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.